ERBB2 and triple-negative breast carcinoma: The association of high ERR1 levels with poor prognoses, particularly in ER-negative/ErbB2(+) and triple-negative breast cancer, has heightened interest in targeting ERR1 and its modulators pharmacologically in breast and other steroidogenic cancers [66, 67].